Stock CALC CALCIMEDICA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus CalciMedica, Inc. OTC Markets

Equities

CALC

US38942Q2021

Market Closed - OTC Markets
Other stock markets
 02:00:01 17/07/2024 am IST 		5-day change 1st Jan Change
4.88 USD +1.46% Intraday chart for CalciMedica, Inc. +9.91% +70.63%
10/07 Oppenheimer Raises CalciMedica's Price Target to $20 From $14, Outperform Rating Maintained MT
09/07 CalciMedica Says First Person Dosed in Phase 2 Trial of Auxora to Treat Acute Kidney Injury MT

Evolution of the average Target Price on CalciMedica, Inc.

Price target over the last 5 years

History of analyst recommendation changes

fea0ad6.hhnQKHeub5sEnwEGHdRu4NSGaXBNuDljR3UGfZqvsIo._kOyGy_iBs88121VTIFclrG_PSc9gHFOBhNwMfzb8_zFYOAFM-Ne8zLYdg~a546aefb2a241708673c5e883bfc303b

Analyst Recommendations on CalciMedica, Inc.

Oppenheimer Raises CalciMedica's Price Target to $20 From $14, Outperform Rating Maintained MT
JonesTrading Initiates CalciMedica With Buy Rating, Price Target is $22 MT
HC Wainwright Starts Coverage on CalciMedica with Buy Rating, $20 Price Target MT
EF Hutton Initiates CalciMedica With Buy Rating, $17 Price Target MT
Wedbush Drops Coverage of Graybug Vision on Termination of GB-102 for Wet Age-Related Macular Degeneration, GB-401 for Primary Open-Angle Glaucoma MT
Piper Sandler Adjusts Graybug Vision's Price Target to $2 From $4, Maintains Neutral Rating MT
Cantor Fitzgerald Adjusts Graybug Vision Price Target to $4 From $6, Maintains Overweight Rating MT
Wedbush Analyst Starts Graybug Vision at Neutral With $3 Price Target, Down From $4 MT
GRAYBUG VISION : Wedbush Adjusts Price Target on Graybug Vision to $4 From $8 on GB-102 Timeline Adjustments; Neutral Rating Kept MT
GRAYBUG VISION : Cantor Fitzgerald Adjusts Price Target for Graybug Vision to $6 From $14, Maintains Overweight Rating MT
GRAYBUG VISION : SVB Leerink Downgrades Graybug Vision to Market Perform From Outperform, Adjusts PT to $5 From $23 MT
GRAYBUG VISION : Needham Downgrades Graybug Vision to Hold from Buy MT
GRAYBUG VISION : Wedbush Downgrades Graybug Vision to Neutral From Outperform on Mixed Results of Phase 2b Altissimo Study MT
GRAYBUG VISION : SVB Leerink Adjusts Graybug Vision's Price Target to $23 from $45, Keeps Outperform Rating MT
GRAYBUG VISION : Piper Sandler Downgrades Graybug Vision to Neutral From Overweight; Price Target is $10 MT
GRAYBUG VISION : Cantor Fitzgerald Starts Graybug Vision at Overweight With $42 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.88 USD
Average target price
18.33 USD
Spread / Average Target
+275.68%
High Price Target
20 USD
Spread / Highest target
+309.84%
Low Price Target
15 USD
Spread / Lowest Target
+207.38%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CalciMedica, Inc.

JonesTrading Institutional Services
HC Wainwright
EF Hutton
Wedbush
Piper Sandler
Cantor Fitzgerald
Needham & Co.
SVB Leerink

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CALC Stock
  4. CALC Stock
  5. Consensus CalciMedica, Inc.